Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2020-02-18 M&A Activity
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Grifols ha suscrito un acuerdo no vinculante (non-binding term sheet) con el fondo Public Investment Fund del Reino de Arabia Saudita.
M&A Activity Classification · 99% confidence The document is a communication from Grifols, S.A. in Spanish, referencing compliance with Article 227 of the Spanish Securities Market Law ('Ley del Mercado de Valores'). It announces a non-binding term sheet agreement with the Public Investment Fund (PIF) of Saudi Arabia to establish a joint venture (JV) for plasma collection centers, fractionation, and purification plants in Saudi Arabia. This type of announcement, detailing a significant business transaction or strategic agreement that is not a standard periodic financial report (like 10-K or IR) or a specific insider trade/dividend notice, falls best under general regulatory announcements or significant corporate actions. Since it is a material, non-standard corporate event disclosure, and does not fit the specific definitions for M&A (TAR - which usually implies a takeover bid or merger proposal), Capital Change (CAP), or Director's Dealing (DIRS), the most appropriate general category for significant, non-standard regulatory disclosures that don't fit elsewhere is 'Regulatory Filings' (RNS). The document is short and serves as an immediate notification of a material event.
2020-02-18 Spanish
6-K
Regulatory Filings
2019-12-06 English
6-K
Regulatory Filings
2019-12-06 English
6-K
Regulatory Filings
2019-11-20 English
6-K
Regulatory Filings
2019-11-15 English
6-K
Regulatory Filings
2019-11-13 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.